Tango Therapeutics, Inc.
TNGXNasdaq
$28.56
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↑ +349.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.1B
Enterprise Value
$3.7B
P/E
—
P/S
71.9
P/B
10.5
EV/EBITDA
—
PEG
—
FCF Yield
-3.5%
Dividend Yield
—
Revenue (TTM)
$57.0M
Net Income (TTM)
-$107.2M
Free Cash Flow (TTM)
-$142.5M
Gross Margin
—
Operating Margin
-206.2%
Net Margin
-188.2%
ROE
-27.4%
ROIC
-795.8%
Debt / Equity
—
Net Cash
$379.8M
Return 1Y
+316.3%
Company profile
Tango Therapeutics, Inc. discovers and develops drugs for the treatment of cancer. Lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. Company also develops Ubiquitin-specific protease 1 and Target 3 for STK11-mutant cancers.
- CEO
- Barbara L. Weber
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Massachusetts
- Website
- tangotx.com
Management & directors
- Crystal AdamPresident, R&D
- Gall MatthewChief Financial Officer
- Beckman DaniellaChief Financial Officer
- Weber BarbaraDirector, Executive Chair
- Peters MaltePresident & CEO
Roles derived from SEC Form 4 filings.
Earnings
TNGX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.32↓ -11.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.7M | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$52.2M | -$58.2M | -$111.1M | -$114.2M | -$145.6M | -$111.3M |
| Net income | -$52.0M | -$58.2M | -$108.2M | -$101.7M | -$130.3M | -$101.6M |
| Diluted EPS | — | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
| Operating cash flow | $70.1M | -$59.5M | -$109.1M | -$118.0M | -$131.5M | -$138.9M |
| Free cash flow | $69.0M | -$61.4M | -$116.8M | -$119.5M | -$132.3M | -$139.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -681.8% | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Net margin | -678.8% | -157.2% | -435.1% | -278.4% | -309.7% | -162.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.9M | $11.6M | $4.1M | $5.4M | $3.2M | $53.8M | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$29.6M | -$32.9M | -$40.9M | -$42.5M | -$41.0M | $14.1M | -$41.9M | -$48.8M |
| Net income | -$25.6M | -$29.2M | -$37.7M | -$39.9M | -$38.9M | $15.9M | -$38.8M | -$45.5M |
| Diluted EPS | -$0.24 | -$0.27 | -$0.33 | -$0.36 | -$0.35 | $0.13 | -$0.29 | -$0.32 |
| Operating cash flow | -$23.6M | -$33.4M | -$36.6M | -$41.7M | -$36.5M | -$31.0M | -$29.7M | -$44.4M |
| Free cash flow | -$23.9M | -$33.5M | -$36.8M | -$41.7M | -$37.1M | -$31.1M | -$29.9M | -$44.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -148.7% | -283.3% | -993.9% | -788.8% | -1287.9% | 26.2% | — | — |
| Net margin | -128.6% | -251.3% | -915.2% | -739.5% | -1221.4% | 29.5% | — | — |
Company news
Jul 2, 2026
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Crystal Adam· President, R&D | Sale | 19,629 | $29.34 | $575,961.97 | filing |
| 2026-07-01 | Crystal Adam· President, R&D | Sale | 7,371 | $30.25 | $222,946.21 | filing |
| 2026-07-01 | Crystal Adam· President, R&D | Option exercise | 27,000 | $5.20 | $140,400.00 | filing |
| 2026-06-19 | Azelby Robert | Award | 5,740 | $0.00 | $0.00 | filing |
| 2026-06-05 | Lee Sung | Award | 570 | $0.00 | $0.00 | filing |
| 2026-06-05 | Ketchum John B | Award | 4,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Calhoun Lesley Ann | Award | 4,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Rothenberg Mace | Award | 4,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | Crystal Adam· President, R&D | Sale | 20,860 | $23.06 | $480,943.99 | filing |
| 2026-06-01 | Crystal Adam· President, R&D | Option exercise | 27,000 | $5.20 | $140,400.00 | filing |
| 2026-06-01 | Crystal Adam· President, R&D | Sale | 6,140 | $22.25 | $136,627.28 | filing |
| 2026-05-01 | Crystal Adam· President, R&D | Sale | 25,900 | $21.19 | $548,901.29 | filing |
| 2026-05-01 | Crystal Adam· President, R&D | Option exercise | 27,000 | $5.20 | $140,400.00 | filing |
| 2026-05-01 | Crystal Adam· President, R&D | Sale | 1,100 | $22.00 | $24,196.04 | filing |
| 2026-05-01 | Gall Matthew· Chief Financial Officer | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-04-29 | Lee Sung | Award | 12,300 | $0.00 | $0.00 | filing |
| 2026-04-15 | Crystal Adam· President, R&D | Sale | 38,460 | $25.00 | $961,500.00 | filing |
| 2026-04-15 | Crystal Adam· President, R&D | Option exercise | 38,460 | $5.20 | $199,992.00 | filing |
| 2026-04-01 | Crystal Adam· President, R&D | Sale | 27,000 | $21.20 | $572,478.30 | filing |
| 2026-04-01 | Crystal Adam· President, R&D | Option exercise | 27,000 | $5.20 | $140,400.00 | filing |
| 2026-03-25 | Crystal Adam· President, R&D | Sale | 12,000 | $20.11 | $241,320.00 | filing |
| 2026-03-25 | Crystal Adam· President, R&D | Option exercise | 12,000 | $5.20 | $62,400.00 | filing |
| 2026-03-05 | Crystal Adam· President, R&D | Sale | 20,251 | $15.00 | $303,765.00 | filing |
| 2026-02-25 | Crystal Adam· President, R&D | Sale | 54,345 | $12.77 | $694,208.46 | filing |
| 2026-02-03 | Weber Barbara· Director, Executive Chair | Sale | 30,186 | $12.26 | $369,998.86 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.